Cancer radiotheranostics targeting carbonic anhydrase-IX with ¹¹¹In- and ⁹⁰Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy.

ABSTRACT: Hypoxic cells dynamically translocate during tumor growth and after radiotherapy. The most desirable direction for therapy targeting hypoxic cells is combining imaging and therapy (theranostics), which may help realize personalized medicine. Here, we conducted cancer radiotheranostics targeting carbonic anhydrase-IX (CA-IX), which is overexpressed in many kinds of hypoxic cancer cells, using low-molecular-weight ¹¹¹In and ⁹⁰Y complexes with a bivalent ureidosulfonamide scaffold as the CA-IX-binding moiety ([¹¹¹In/⁹⁰Y]US2). Methods: The targeting ability of [¹¹¹In]US2 was evaluated by in vivo biodistribution study in CA-IX high-expressing (HT-29) tumor-bearing mice. In vivo imaging of HT-29 tumors was carried out us

SUBMITTER: Iikuni S 

PROVIDER: S-EPMC5996370 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature